Alymsys (bevacizumab-maly) vs bevacizumab-awwb

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

bevacizumab-awwb · MVASI

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT01966003 · Phase 3 · completed

This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.

Reported efficacy

Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)

Result source: NCT01966003

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)bevacizumab-awwb
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT032961636.6 vs 7.9vs Bevacizumabn 328NCT01966003
OS, median—Not reported—Not reported
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT0329616339% vs 41.7%vs Bevacizumabn 328NCT01966003
Duration of response, median—Not reported5.8 vs 5.6vs Bevacizumabn 128NCT01966003

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
bevacizumab-awwb
6.6 vs 7.9vs Bevacizumabn 328NCT01966003

OS, median

Alymsys (bevacizumab-maly)
—Not reported
bevacizumab-awwb
—Not reported

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
bevacizumab-awwb
39% vs 41.7%vs Bevacizumabn 328NCT01966003

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
bevacizumab-awwb
5.8 vs 5.6vs Bevacizumabn 128NCT01966003
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · bevacizumab-awwb: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)bevacizumab-awwb
Dropout rate
34.3%a
NCT03296163 · Phase 3
82.3%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—a
NCT03296163 · Phase 3
—
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
18.6%a
NCT03296163 · Phase 3
26.2%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3
alopecia 43.2%
nausea 25.3%
anaemia 20.1%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bevacizumab-awwb

Duration of Response 5.8 vs 5.6 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · bevacizumab-awwb's landscape